Orladeyo
Authorised
This medicine is authorised for use in the European Union
berotralstat
MedicineHumanAuthorised
Overview
Orladeyo is a medicine used to prevent attacks of hereditary angioedema (swelling) in patients from 12 years of age. Patients with hereditary angioedema have attacks of rapid swelling such as in the face, throat, arms and legs, or around the gut.
Hereditary angioedema is rare, and Orladeyo was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 27 June 2018. Further information on the orphan designation can be found here.
Orladeyo contains the active substance berotralstat.
Orladeyo is available as capsules and can only be obtained with a prescription. The recommended dose is one 150-mg capsule daily taken with food.
For more information about using Orladeyo, see the package leaflet or contact your healthcare provider.
The active substance in Orladeyo, berotralstat, works by blocking the activity of a protein called kallikrein. In patients with angioedema, overactive kallikrein leads to raised levels of another protein, bradykinin. Bradykinin is involved in a process that causes blood vessels to widen and become leaky. resulting in the swelling and inflammation of angioedema attacks. Blocking the activity of kallikrein reduces the number of these attacks.
Orladeyo was effective at preventing attacks of angioedema in one main study of 121 patients with hereditary angioedema. Patients taking 150 mg Orladeyo every day for 24 weeks had an average of 1.3 attacks per month, compared with 2.4 attacks per month in patients taking placebo (a dummy treatment).
The most common side effects with Orladeyo (which may affect more than 1 in 10 people) are headache, abdominal (belly) pain and diarrhoea. Abdominal pain and diarrhoea, which can occur about 1 to 3 months after starting Orladeyo, get better as treatment continues.
For the full list of side effects and restrictions with Orladeyo, see the package leaflet.
Orladeyo is effective at reducing the number of angioedema attacks, including life-threatening throat swelling. The medicine can be taken by mouth and its side effects were manageable. The European Medicines Agency therefore decided that Orladeyo’s benefits are greater than its risks and it can be authorised for use in the EU.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Orladeyo have been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Orladeyo are continuously monitored. Side effects reported with Orladeyo are carefully evaluated and any necessary action taken to protect patients.
Orladeyo received a marketing authorisation valid throughout the EU on 30 April 2021.
Product information
Latest procedure affecting product information: IB/0011
13/12/2022
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Orladeyo
- Active substance
- berotralstat dihydrochloride
- International non-proprietary name (INN) or common name
- berotralstat
- Therapeutic area (MeSH)
- Angioedemas, Hereditary
- Anatomical therapeutic chemical (ATC) code
- B06AC
Pharmacotherapeutic group
Other hematological agentsTherapeutic indication
Orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.
News on Orladeyo
This page was last updated on